

Barcelona, February 8th 2016

SIGNIFICANT EVENT

Almirall closes the acquisition of Poli Group

Almirall, S.A. (ALM.MC), as per section 228 of the Royal Legislative Decree 4/2015, of 23 October 2015, approving the Restated Text of the Securities Market Act, hereby announces that:

It has closed an agreement to acquire one hundred per cent of the share capital of Poli Group Holding S.r.l., the holding company of Poli Group, having fulfilled all regulatory and anti-trust requirements. Poli Group comprises three operating companies (Taurus Pharma GbmH, Polichem S.A. and Polichem S.r.l.).

Poli Group's products are commercialized in 70 countries, with a focus on Europe and Asia. For the last 12 months ending in June 2015, Poli Group generated net sales close to ~€85 million. Poli Group has a diversified portfolio of proprietary and well-established drugs, focused on Dermatology and complemented with a strong portfolio of gynecology and respiratory products, the latter promoted through distributors.

With this acquisition Almirall will obtain a dermatology focused R&D structure with a proprietary formulation technology (HPCH) and three clinical stage Dermatology products.

With this strategic transaction Almirall continues to execute its plan to become a top global Dermatology player.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations Department
inversores@almirall.com

